title: Pharmacokinetics, safety and tissue residues of sustained-release sulfamethazine in sheep.
abstract: Concentration-time profiles and the rates of absorption, extent of distribution and half-lives of sulfamethazine (SMZ), administered intravenously, orally as a water solution and as a sustained-release formulation (CalfSpan) were determined in 10 healthy sheep. The geometric mean half-life of elimination of i.v. SMZ was 10.8 h, compared to 14.3 h for the sustained-release preparation (CalfSpan) and 4.3 h for the oral water solution. Blood levels of SMZ were at or above 50 micrograms/ml for more than 48 h for CalfSpan, for 24 h after i.v. SMZ (100 mg/kg body wt), and for less than 24 h after p.o. SMZ (100 mg/kg body wt). The mean bioavailability of the oral SMZ solution was 58.3% (AUCp.o./AUCi.v.). The estimated bioavailability of the CalfSpan preparation was 52.5%. The safety of the sustained-release preparation was tested by dosing sheep with multiples (one, three and five times) of the recommended dose (one tablet, 8 g SMZ, per 20 kg body wt), once a day for 3 days. Clinical blood chemistries showed a significant increase in serum iron, and a decrease in serum phosphorus in animals treated at the 3x and 5x dose levels. Necropsies of the 5x dose animals did not show any gross signs that could be attributed to SMZ, and histological examination of tissues from the 5x animals revealed no organ pathology. Residues of SMZ in liver, fat, kidney and skeletal muscle were measured in 20 animals that received one bolus per 20 kg body wt. The results indicate that SMZ residues are cleared rapidly, and are at or below the tolerance level of 0.1 mg/kg within 8 days after dosing so that the 18-day withdrawal time used in cattle would provide an appropriate margin of safety if used in sheep.
authors.affiliation: Caldwell Veterinary Teaching and Research Center, University of Idaho 83605.
authors.forename: M S
authors.initials: MS
authors.lastname: Bulgin
authors.forename: V M
authors.initials: VM
authors.lastname: Lane
authors.forename: T E
authors.initials: TE
authors.lastname: Archer
authors.forename: J D
authors.initials: JD
authors.lastname: Baggot
authors.forename: A L
authors.initials: AL
authors.lastname: Craigmill
mesh_terms: D000284:Administration, Oral; D000818:Animals; D003692:Delayed-Action Preparations; D005260:Female; D006207:Half-Life; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D012756:Sheep / Q000378:metabolism*; D013418:Sulfamethazine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D003692:Delayed-Action Preparations; D013418:Sulfamethazine